Navigation Links
Titan Reports Fourth Quarter 2010 Fanapt® Royalty

SAN FRANCISCO, Feb. 3, 2011 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (OTC Bulletin Board: TTNP) today reported that the company expects to receive a royalty payment of approximately $409,000 on fourth quarter 2010 net sales of Fanapt (iloperidone) of approximately $5.1 million. Prescriptions for Fanapt continued a steady growth trend during the fourth quarter according to analyst reports which showed that the fourth quarter 2010 average weekly prescriptions increased to 1,876 from the third quarter 2010 average weekly prescriptions of 1,449.

About Titan Pharmaceuticals

For information concerning Titan Pharmaceuticals, Inc., please visit the Company's website at

The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.

SOURCE Titan Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Titan Pharmaceuticals Announces Second Quarter 2010 Financial Results
2. Cardiac Dimensions® Announces Presentation of 12-Month Follow-up Data of TITAN™ Trial at European Society of Cardiology Meeting
3. Ascension Orthopedics Receives FDA Approval for TITAN™ Modular Total Shoulder System
4. Ascension Orthopedics Announces First Implantations of TITAN™ Modular Shoulder
5. Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine™ Data
6. Ascension Orthopedics Announces Implantation of the TITAN™ Modular Total Shoulder
7. Ascension Orthopedics Implants PyroTITAN™ in France
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
(Date:11/30/2015)... 2015   Royal Philips  (NYSE: PHG ... Radiology Solutions, a fully integrated, consultative approach to ... data-driven practice management approaches that combine imaging systems, ... improve care delivery and reduce costs. Making its ... North America Annual Meeting (RSNA) in ...
(Date:11/30/2015)... -- global cell culture market is expected to ... by 2022 at a CAGR of 7.1% therein. --> ... 2013 value of US$6.1 bn to US$11.3 bn by 2022 at ... has announced the release of a new market research study, detailing ... Culture Market - Global Industry Analysis, Size, Share, Growth, Trends and ...
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... Implant, the industry,s first MRI guided user interface and ... of patients with MR Conditional implants, such as knee ... 2015 Radiological Society of North America Annual Meeting ... and supports diagnostic confidence of this growing patient population. ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 30, 2015 , ... Until now, the St. Louis Fetal Care Institute ... of Myelomeningocele Study) trial. One of these exclusion criteria was a BMI above 34.9. ... to 24.9 is considered normal, 25 - 29.9 is overweight and above 30 is ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a world ... announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking and ... platform which uses temperature as a clinical endpoint. The technology has been ...
(Date:11/30/2015)... ... November 30, 2015 , ... The world of hair transplants and restoration is ... These techniques and procedures have been in use for many years and are among ... Parsa Mohebi, M.D. has utilized many of these methods over the years, he also ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally ... styling. So why is it a national news story when Donald Trump makes disparaging ... M.D., because appearances count more than anyone wants to admit when it comes to ...
(Date:11/30/2015)... , ... November 30, 2015 , ... According to Los ... people to overeat are not necessarily caused by real hunger, but instead by ... needs food. He notes that, while many patients are aware that weight loss surgery ...
Breaking Medicine News(10 mins):